NR (Nicotinamide Riboside) Research Overview (also known as Nicotinamide riboside chloride, NR, Niagen)
Nicotinamide riboside (NR) is a naturally occurring form of vitamin B3 and a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme required for mitochondrial energy metabolism, redox reactions, DNA repair, and cellular signaling. Research primarily evaluates oral NR supplementation for effects on NAD+ biology, aging-related physiology, metabolic health, mitochondrial function, and exercise or energy-related outcomes.
What Is NR (Nicotinamide Riboside)?
Nicotinamide riboside, commonly abbreviated NR, is a pyridine-nucleoside form of vitamin B3 composed of nicotinamide linked to ribose. It occurs in trace amounts in some foods and is also produced commercially, frequently as nicotinamide riboside chloride. NR is studied because it can serve as a dietary precursor to nicotinamide adenine dinucleotide, or NAD+, a central coenzyme involved in energy production, redox balance, DNA repair, chromatin regulation, and cellular stress responses.
NAD+ concentrations and the activity of NAD+-dependent enzymes may change with age, tissue type, metabolic state, inflammation, and cellular damage. Oral NR has therefore become a research tool for testing whether increasing NAD+ availability can influence human physiology. Human trials have generally focused on pharmacokinetics, tolerability, blood NAD+ metabolites, skeletal-muscle metabolism, cardiovascular measures, insulin sensitivity, and markers associated with aging. NR is not established as a treatment for aging, disease, fatigue, or any other medical condition, and responses may differ according to baseline NAD+ status, dose, duration, diet, exercise, and health status.
Research Indications
NAD+ Metabolism
Raises circulating NAD+ metabolites
Human supplementation studies consistently show increased whole-blood NAD+ and related nicotinamide metabolites after oral NR administration.
Bioavailable NAD+ precursor
NR is converted through the nicotinamide riboside kinase pathway to NMN and NAD+, supporting cellular redox cofactor availability.
Healthy Aging & Vascular Function
Blood pressure and arterial stiffness
A small trial in middle-aged and older adults reported signals consistent with reduced systolic blood pressure and improved arterial stiffness, particularly in participants with elevated baseline pressure.
Inflammatory signaling
Human skeletal-muscle data identified transcriptomic changes including anti-inflammatory signatures; clinical relevance remains uncertain.
Exercise & Mitochondrial Function
Mitochondrial outcomes
Despite reliably increasing NAD+ metabolites, controlled human studies have not consistently demonstrated improved skeletal-muscle mitochondrial respiration.
Physical performance
Evidence for improved exercise capacity, strength, or recovery in healthy adults is limited and mixed.
Metabolic Health
Insulin sensitivity
Trials in people with insulin resistance or obesity have not established a consistent clinically meaningful benefit for insulin sensitivity or glycemic control.
Body composition
NR should not be considered an evidence-based intervention for weight loss or changes in fat mass.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Initial tolerability research | 100–300 mg | Once daily | Oral |
| NAD+ elevation studies | 500–1,000 mg | Once daily | Oral |
| Healthy aging trials | 1,000 mg | Once daily | Oral |
| Higher-dose safety studies | 2,000 mg | Once daily | Oral |
Timing
Clinical studies commonly use once-daily oral dosing, with or without food. Morning dosing is often selected for consistency and to simplify monitoring; taking with food may improve gastrointestinal comfort for some individuals.
Peptide Interactions
Both are NAD+ precursors. Concurrent use is usually redundant and has limited human research supporting added benefit.
Both contribute to the NAD+ salvage network, but high-dose combination strategies have not been shown to produce superior clinical outcomes.
The proposed NAD+/sirtuin rationale is mechanistic; robust human evidence for a combined longevity or performance effect is lacking.
Potential metabolic overlap is under study. People using glucose-lowering medication should monitor with their prescriber rather than self-managing a combination.
Exercise independently supports mitochondrial and cardiometabolic health; NR is not a substitute for training, and additive effects remain unproven.
NAD+ metabolism is relevant to tumor biology and treatment response. Use during active cancer treatment should be reviewed by the oncology team.
Reported Research Timeline
01Days 1–7 (reported in cited studies): most people notice no acute subjective effect. Mild gastrointestinal upset, nausea, headache, or fatigue may occur in sensitive individuals.
02Weeks 1–2 (reported in cited studies): circulating NAD+ metabolites can rise during this period, although this biochemical change is not necessarily felt.
03Weeks 3–6 (reported in cited studies): if tolerated, routines are generally assessed for adherence and any changes in sleep, digestion, energy, or concurrent medication effects.
04Weeks 6–12 (reported in cited studies): this is the duration used by several controlled trials for vascular, metabolic, and muscle-related endpoints; benefits remain variable and often not clinically apparent.
05Months 3–6 (reported in cited studies): reassess whether there is a measurable, personally relevant reason to continue rather than assuming NAD+ elevation alone predicts a health benefit.
06Beyond 6 months: Long-term use should be periodically reviewed, especially when health status, prescriptions, pregnancy plans, or cancer risk change.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Human studies generally report NR as well tolerated over weeks to months, but long-term outcome data are limited.
Reported adverse effects may include nausea, indigestion, abdominal discomfort, diarrhea, headache, fatigue, or flushing-like sensations.
Avoid assuming that a higher dose produces greater health benefit; dose-response relationships for most wellness outcomes are not established.
People with liver or kidney disease should seek clinician guidance because data in these populations are limited.
Pregnancy, breastfeeding, and pediatric use lack adequate safety data and should be avoided unless specifically directed by a clinician.
Seek Medical Attention If:
You develop signs of a severe allergic reaction, including facial or throat swelling, wheezing, hives, or difficulty breathing.
You experience persistent vomiting, severe abdominal pain, dark urine, jaundice, or other possible signs of liver injury.
You have fainting, chest pain, a sustained rapid heartbeat, or severe new neurologic symptoms.
You are undergoing cancer treatment or develop a new cancer diagnosis and have not discussed supplementation with your oncology team.
Quality Indicators
Verified Marker
Batch-specific certificate of analysis
Look for a current, lot-matched COA identifying the product, lot number, test date, and quantitative NR result.
Verified Marker
Independent identity and purity testing
Prefer third-party HPLC or LC-MS testing that reports identity confirmation and assay purity rather than a generic in-house statement.
Verified Marker
Contaminant screening
A quality report should include heavy-metal and microbiological testing, with results and method limits rather than unsupported claims.
Acceptable Range
Accurate capsule labeling
The label should state elemental NR quantity per capsule and serving, excipients, capsule material, storage conditions, and expiration date.
Quality Concern
Unverifiable purity or proprietary blends
Avoid products without batch documentation, products that obscure NR dose within a blend, or vendors making pharmaceutical-grade claims without evidence.
Research Citations
- Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell, S. A. J., Schmidt, M. S., Weidemann, B. J., et al., 2016, Nature Communications - Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in middle-aged and older adults
Martens, C. R., Denman, B. A., Mazzo, M. R., et al., 2018, Nature Communications - Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures
Elhassan, Y. S., Kluckova, K., Fletcher, R. S., et al., 2019, Cell Metabolism - An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside and its effects on blood NAD+ levels in healthy volunteers
Airhart, S. E., Shireman, L. M., Risler, L. J., et al., 2017, PLOS ONE - Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults
Conze, D., Brenner, C., Kruger, C. L., 2019, Scientific Reports
Research Focus
longevity, NAD+ metabolism, mitochondrial function, cellular energy, aging biology, metabolic health, DNA repair, sirtuins
Frequently Asked Questions
What should researchers watch for with NR (Nicotinamide Riboside)?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with NR (Nicotinamide Riboside)?
Days 1–7 (reported in cited studies): most people notice no acute subjective effect. Mild gastrointestinal upset, nausea, headache, or fatigue may occur in sensitive individuals.
How is NR (Nicotinamide Riboside) typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →